Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Tabula Rasa Healthcare: New Study Predicts Risks of Drug Interactions without Exposing Patients to Harm

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medication, and Regence Health Plans today announced the results of a simulation-based clinical study which demonstrates that TRHC’s MedWise® medication risk score can be used to assess drug safety without exposing real people to actual harm.

The study, published online in Clinical and Translational Science, used TRHC’s proprietary MedWise medications safety technology to virtually assess the potential risk of adverse drug events (ADEs) when adding repurposed drugs for COVID-19 treatment to the individual medications of a large-scale population. The results demonstrate that medication risk scores could be used to effectively assess drug safety before exposing patients to repurposed drugs.

“Through this innovative simulation we have demonstrated the value of our MedWise technology as part of a blueprint to assess the safety of newly prescribed repurposed drugs without exposing real patients to potential harm,” said TRHC Chairman and CEO Calvin H. Knowlton, Ph.D. “By partnering with Regence Health Plans, we have confirmed a powerful preemptive tool to identify individuals at higher risk of adverse drug events, to foresee types of potential risks, and to pin-point drugs to be monitored on an individual level.”

The simulated risk assessment examined de-identified medical information from approximately 500,000 Medicare and commercially insured Regence Health Plan members. Researchers determined each person’s baseline MedWise Risk Score™ (MRS) and simulated the addition of five drugs repurposed for COVID-19 treatment. The change in the MedWise Risk Score was used as a predictive tool to assess the risk of adverse drug events associated with repurposed drugs for COVID-19.

“Using a simulation-based approach, we are able to apply scientific data on the drugs’ mechanisms and metabolisms to determine how these drugs would alter a patient’s medication risk score—without putting the patients at risk,” said Veronique Michaud, Chief Operating Officer, TRHC Precision Pharmacotherapy Research and Development Institute. “We can use this data to identify patients at higher risk of adverse drug events from large populations. Once identified, our TRHC MedWise Advisor services can provide appropriate individual recommendations to mitigate the risk of ADEs.”

“We are very pleased to be a part of this novel simulation-based clinical study,” said Matthew Hafermann, a Regence’s Clinical Pharmacist. “The simulation strategy using a medication risk score represents an innovative approach to furthering patient safety by preemptively estimating the risk of adverse drug events.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine